The Trump administration has expanded TrumpRx to include more than 600 generic medications — a significant scale-up from the platform’s original focus on branded drugs under most-favored-nation ...

More than 600 generics will be available through the website, Trump said, part of an effort by the administration to expand access to lower-cost medicines. TrumpRx, launched in January, is part of ...

Minecraft's Java Edition has long been the go-to for PC players, owing to how moddable it is in comparison to its Bedrock counterpart. However, getting a clean multiplayer experience has long ...

The chief executive of generic-drug maker Sandoz SDZ0.53%increase; green up pointing triangle Group expects the market for unbranded versions of popular weight-loss medicines to be big. Just how big, ...

Type to search articles, cases, and authors. Press ↵ to view all results. Updated on Apr. 30 at 8:35 p.m. Yesterday’s argument in Hikma Pharmaceuticals USA v Amarin Pharma showed a bench once again ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BENGALURU -- Indian drugmaker Sun Pharma said on Monday that it will fork out $11.75 billion in cash to buy U.S.-based Organon, underscoring a broader push by pharmaceutical companies in the South ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

Over the last year, Sanofi has been busy reshaping itself to focus more on innovative drugs, including selling a controlling stake in its former consumer business and using those proceeds to strike a ...

Merck KGaA forecast lackluster earnings in guidance that reflects generic competition for its multiple sclerosis blockbuster drug Mavenclad, but not the potential benefits from the US launch of a ...

A revolution is coming in the U.S. generics marketplace, one that has the potential to transform savvy organizations into engines of growth, and to end the decades-long “race to the bottom” that for ...